Slowly progressive dopamine cell loss - A model on which to test neuroprotective strategies for Parkinson's disease?

Reviews in the Neurosciences

Volumn 20, Issue 2, 2009, Pages 85-94

  Wright, Ann K ^b   Garcia Munoz, Marianela ^a   Arbuthnott, Gordon W ^a  

^a OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY GRADUATE UNIVERSITY   (Japan)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Basal ganglia; Dopamine; Globus pallidus; Microglia; Neurodegeneration; Subthalamic nucleus

Indexed keywords

CYCLOSPORIN A; IBOTENIC ACID; OXIDOPAMINE; TACROLIMUS;

CELL LOSS; DISEASE COURSE; DOPAMINERGIC NERVE CELL; GLOBUS PALLIDUS; NERVE CELL NECROSIS; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA; SWEDEN;

EID: 69749104987     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/REVNEURO.2009.20.2.85     Document Type: Review

References (103)

1. Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nature Reviews 2006; 7: 207-219. (Pubitemid 43292466)
2. Absi E, Ayala A, Machado A, et al. Protective effect of melatonin against the 1-methyl-4-phenylpyridinium-induced inhibition of Complex I of the mitochondrial respiratory chain. J Pineal Res 2000; 29: 40-47. (Pubitemid 30449700)
3. Akiyama H, McGeer PL. Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Res 1989; 489: 247-253. (Pubitemid 19149247)
4. Albin RL, Young AB, Penney JB. The functional anatomy of disorders of the basal ganglia. Trends Neurosci 1995; 18: 63-64.
5. Alvarez L, Macias R, Guridi J, et al. Dorsal subthalamotomy for Parkinson's disease. Mov Disord 2001; 16: 72-78.
6. Arbuthnott G, Dejean C, Hyland B. Antidromic cortical activity as the source of therapeutic actions of deep brain stimulation? Cortico-subcortical dynamics in Parkinson's disease, ed Tseng, K.Y. Humana Press. New York 2008.
7. Ashby P, Paradiso G, Saint-Cyr JA, et al. Potentials recorded at the scalp by stimulation near the human subthalamic nucleus. Clin Neurophysiol 2001; 112: 431-437. (Pubitemid 32166922)
8. Ashby P, Rothwell JC. Neurophysiologic aspects of deep brain stimulation. Neurology 2000; 55: S17-S20. (Pubitemid 32103938)
9. Augood SJ, Emson PC, Mitchell IJ, et al. Cellular localisation of enkephalin gene expression in MPTP-treated cynomolgus monkeys. Brain Res Mol Brain Res 1989; 6: 85-92.
10. Bakay RAE, DeLong MR, Vitek JL. Posteroventral pallidotomy for Parkinson's disease. J Neurosurg 1992; 77: 487-488.
11. Baufreton J, Atherton JF, Surmeier DJ, et al. Enhancement of excitatory synaptic integration by GABAergic inhibition in the subthalamic nucleus. J Neurosci 2005; 25: 8505-8517. (Pubitemid 41324736)
12. Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta 1998; 1366: 211-223.
13. Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci 1993; 16: 125-131.
14. Benabid AL, Pollak P, Gross C, et al. Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease. Stereotact Funct Neurosurg 1994; 62: 76-84.
15. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990; 249: 1436-1438. (Pubitemid 20341910)
16. Bevan MD, Magill PJ, Hallworth NE, et al. Regulation of the timing and pattern of action potential generation in rat subthalamic neurons in vitro by GABA-A IPSPs. J Neurophysiol 2002; 87: 1348-1362.
17. Bevan MD, Wilson CJ. Mechanisms underlying spontaneous oscillation and rhythmic firing in rat subthalamic neurons. J Neurosci 1999; 19: 7617-7628.
18. A current and implications for rebound burst firing in rat subthalamic neurons in vitro. J Neurophysiol 2000; 83: 3169-3172.
19. Boulet S, Lacombe E, Carcenac C, et al. Subthalamic stimulation-induced forelimb dyskinesias are linked to an increase in glutamate levels in the substantia nigra pars reticulata. J Neurosci 2006; 26: 10768-10776. (Pubitemid 44776834)
20. Brooks DJ. Dopamine agonists: their role in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 68: 685-689. (Pubitemid 30265265)
21. Butcher SP, Henshall DC, Teramura Y, et al. Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism. J Neurosci 1997; 17: 6939-6946. (Pubitemid 27427872)
22. Celada P, Paladini CA, Tepper JM. GABAergic control of rat substantia nigra dopaminergic neurons: role of globus pallidus and substantia nigra pars reticulata. Neuroscience 1999; 89: 813-825. (Pubitemid 29071006)
23. Chase TN, Verhagen Metman L, Bravi D, et al. Dopamine-receptor subtype-selective agonists in the treatment of Parkinson's disease. Clin Neuropharmacol 1995; 18(Suppl 1): S207-S215.
24. Day M, Wang Z, Ding J, et al. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 2006; 9: 251-259. (Pubitemid 43164549)
25. Dewar D, Jenner P, Marsden CD. Lesions of the globus pallidus, entopeduncular nucleus and substantia nigra alter dopamine mediated circling behaviour. Exp Brain Res 1983; 52: 281-292.
26. Dunnett SB, Björklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 1999; 399: A32-A39. (Pubitemid 129519186)
27. Ehrlich LC, Hu S, Sheng WS, et al. Cytokine regulation of human microglial cell IL-8 production. J Immunol 1998; 160: 1944-1948. (Pubitemid 28106484)
28. Filion M. Effects of interruption of the nigrostriatal pathway and of dopaminergic agents on the spontaneous activity of globus pallidus neurons in the awake monkey. Brain Res 1979; 178: 425-441. (Pubitemid 10194665)
29. Filion M, Tremblay L, Bedard PJ. Abnormal influences of passive limb movement on the activity of globus pallidus neurons in Parkinsonian monkeys. Brain Res 1988; 444: 165-176. (Pubitemid 18071205)
30. Filion M, Tremblay L, Bedard PJ. Responses of the globus pallidus neurons to electrical stimulation of the striatum and the passive joint rotation in MPTP treated monkeys. Abstr Soc Neurosci 1986; 1: 208-208
31. Filion M, Tremblay L, Bedard PJ, et al. Excessive and unselective responses of medial pallidal neruons to both passive movement and striatal stimulation in monkeys with MPTP-induced parkinsonism. In: Neural Mechanisms in Disorders of Movement. London: John Libbey & Company Ltd, 1989; 157-164.
32. Fraix V, Houeto JL, Lagrange C, et al. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease. J Neurol Neurosurg Psychiatry 2006; 77: 443-449.
33. Fuxe K, Corrodi H, Hökfelt T, et al. Ergocamine and 2 Br-a-ergocrytptine. Evidence for prolonged dopamine receptor stimulation. Med Biol 1974; 52: 121-132.
34. Gao DM, Benazzouz A, Piallat B, et al. High-frequency stimulation of the subthalamic nucleus suppresses experimental resting tremor in the monkey. Neuroscience 1898; 88: 201-212.
35. Gerfen CR, McGinty JF, Scott Young W. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J Neurosci 1991; 11: 1016-1031.
36. Gerfen CR, Wilson CJ, Swanson LW, et al. The basal ganglia. In: Björkland A, Hökfelt T, eds. Integrated Systems of the CNS, Part III. Cerebellum, Basal Ganglia and Olfactory System. Amsterdam: Elsevier Press, 1996.
37. Giovanni A, Sieber BA, Heikkila RE, et al. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration. J Pharmacol Exp Ther 1994; 270: 1000-1007.
38. Giovanni A, Sonsalla PK, Heikkila RE. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. J Pharmacol Exp Ther 1994; 270: 1008-1014.
39. Hallworth NE, Wilson CJ, Bevan MD. Apamin-sensitive small conductance calcium-activated potassium channels, through their selective coupling to voltage-gated calcium channels, are critical determinants of the precision, pace, and pattern of action potential generation in rat subthalamic nucleus neurons in vitro. J Neurosci 2003; 23: 7525-7542.
40. Hamada I, Delong MR. Excitotoxic acid lesions of the primate subthalamic nucleus result in transient dyskinesias of the contralateral limbs. J Neurophysiol 1992; 68: 1850-1858.
41. Hassani OK, Mouroux M, Feger J. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience 1996; 72: 105-115. (Pubitemid 26092990)
42. Hökfelt T, Ungerstedt U. Electron and fluorescent microscopical studies on the nucleus caudatus putamen of the rat after unilateral lesions of ascending nigroneostriatal dopamine neurons. Acta Physiol Scand 1969; 76: 415-426.
43. Ingham CA, Hood SH, Arbuthnott GW. A light and electron microscopical study of enkephalin-immunoreactive structures in the rat neostriatum after removal of the nigrostriatal dopaminergic pathway. Neuroscience 1991; 42: 715-730.
44. Ingham CA, Hood SH, Arbuthnott GW. Spine density on neostriatal neurons changes with 6-hydroxydopamine lesions and with age. Brain Res 1989; 503: 334-338.
45. Ingham CA, Hood SH, Taggart P, et al. Plasticity of synapses in the rat neostriatum after unilateral lesion of the nigrostriatal dopaminergic pathway. J Neurosci 1998; 18: 4732-4743. (Pubitemid 28280181)
46. Ingham CA, Los I, Hood SH, et al. Enkephalin and GABA immunoreactive boutons in the rat globus pallidus after unilateral removal of the nigrostriatal dopaminergic pathway. Neurosci Lett Suppl 1992; 42: 36-36
47. Iribe Y, Moore K, Pang KCH, et al. Subthalamic stimulation-induced synaptic responses in substantia nigra pars compacta dopaminergic neurons in vitro. J Neurophysiol 1999; 82: 925-933. (Pubitemid 29387864)
48. Jonsson G, Fuxe K, Hamberger B, et al. 6-Hydroxytryptamine - a new tool in monoamine fluorescence histochemistry. Brain Res 1969; 13: 190-195.
49. Koos T, Tepper JM. Inhibitory control of neostriatal projection neurons by GABAergic interneurons. Nat Neurosci 1999; 2: 467-472. (Pubitemid 30491258)
50. Krack P, Limousin P, Benabid AL, et al. Chronic stimulation of subthalamic nucleus improves levodopainduced dyskinesias in Parkinson's disease. Lancet 1997; 350: 1676. (Pubitemid 28036831)
51. Lee CR, Abercrombie ED, Tepper JM. Pallidal control of substantia nigra dopaminergic neuron firing pattern and its relation to extracellular neostriatal dopamine levels. Neuroscience 2004; 129: 481-489.
52. Li S, Arbuthnott GW, Jutras MJ, et al. Resonant antidromic cortical circuit activation as a consequence of high-frequency subthalamic deep-brain stimulation. J Neurophysiol 2007; 98: 3525-3537.
53. Limousin P, Pollak P, Benazzouz A, et al. Bilateral subthalamic nucleus stimulation for severe Parkinson's disease. Mov Disord 1995; 10: 672-674.
54. Limousin P, Pollak P, Benazzouz A, et al. Effect on Parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995; 345: 91-95.
55. Ljungberg T, Ungerstedt U. Sensory inattention produced by 6-hydroxy-dopamine-induced degeneration of ascending dopamine neurons in the brain. Exp Neurol 1976; 53: 585-600. (Pubitemid 8023316)
56. Luquin MR, Saldise L, Guillen J, et al. Does increased excitatory drive from the subthalamic nucleus contribute to dopaminergic neuronal death in Parkinson's disease? Exp Neurol 2006; 201: 407-415.
57. Marshall JF, Ungerstedt U. Striatal efferent fibres play a role in maintaining rotational behaviour in the rat. Science 1977; 198: 62-64. (Pubitemid 8196224)
58. Martin JP. Hemichorea resulting from a local lesion of the brain (the syndrome of the body of Luys). Brain 1927; 50: 637-651.
59. McGeer PL, Itagaki S, Boyes BE, et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38: 1285-1291. (Pubitemid 18218619)
60. Miller WC, Delong MR, Carpenter MB, et al. Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In: The Basal Ganglia: Structure and Function. New York: Plenum Press, 1987; 415-429.
61. Mizuno Y. Drug therapy of Parkinson's disease. An overview. Eur Neurol 1992; 32 (Suppl 1): 3-8.
62. Montastruc JL, Rascol O, Senard JM. Treatment of Parkinson's disease should begin with a dopamine agonist. Mov Disord 1999; 14: 725-730. (Pubitemid 29509613)
63. Obeso JA, Guridi J, Rodriguez-Oroz MC, et al. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001; 345: 956-963. (Pubitemid 34940811)
64. Obeso JA, Rodriguez-Oroz MC, Javier Blesa F, et al. The globus pallidus pars externa and Parkinson's disease. Ready for prime time? Exp Neurol 2006; 202: 1-7.
65. Ogawa N. Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease. Neurology 1998; 51: S13-S20. (Pubitemid 28397138)
66. Ogawa N. Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages. Eur Neurol 1994; 34 (Suppl 3): 20-28. (Pubitemid 24294542)
67. A receptors in vivo. Neuroscience 1999; 89: 799-812. (Pubitemid 29071005)
68. Perier C, Agid Y, Hirsch EC, et al. Ipsilateral and contralateral subthalamic activity after unilateral dopaminergic lesion. NeuroReport 2000; 11: 3275-3278. (Pubitemid 30780511)
69. Piccoli F, Riuggeri RM. Dopaminergic agonists in the treatment of Parkinson's disease: a review. J Neural Transm 1995; 102 (Suppl 45): 187-195.
70. Poewe W. Should treatment of Parkinson's disease be started with a dopamine agonist? Neurology 1998; 51: S21-S24.
71. Pollak P, Benabid AL, Limousin P, et al. Subthalamic nucleus stimulation alleviates akinesia and rigidity in Parkinsonian patients. Adv Neurol 1996; 69: 591-594.
72. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 1998; 44: S175-S188.
73. Rouzaire-Dubois B, Hammond C, Hamon B, et al. Pharmacological blockade of the globus pallidus-induced inhibitory response of subthalamic cells in the rat. Brain Res 1980; 200: 321-329. (Pubitemid 10006955)
74. Sachs C, Jonsson G. Commentary: Mechanisms of action of 6-hydroxydopamine. Biochem Pharmacol 1975; 24: 1-8.
75. Schallert T, Upchurch M, Wilcox RE, et al. Pressure-independent sensorimotor analysis of inter-hemispheric receptor asymmetries in neostriatum. Pharmacol Biochem Behav 1983; 18: 753-759.
76. Schallen T, Whishaw IQ, Ramirez VD, et al. Compulsive, abnormal walking caused by anticholinergics in akinetic, 6-hydroxydopamine-treated rats. Science 1978; 199: 1461-1463.
77. Schapira AHV. Present and future drug treatment for Parkinson's disease. J Neurol Neurosurg Psychiatry 2005; 76: 1472-1478. (Pubitemid 41531688)
78. Sinclair SR, Fawcett JW, Dunnett SB. Dopamine cells in nigral grafts differentiate prior to implantation. Eur J Neurosci 1999; 11: 4341-4348.
79. Stacy M, Jankovic J. Current approaches in the treatment of Parkinson's disease. Annu Rev Med 1993; 44: 431-440. (Pubitemid 23117880)
80. Stephens B, Mueller AJ, Shering AF, et al. Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience 2005; 132: 741-754. (Pubitemid 40503224)
81. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 2007; 30: 244-250. (Pubitemid 46667168)
82. Teagarden M, Atherton JF, Bevan MD, et al. Accumulation of cytoplasmic calcium, but not apamin-sensitive afterhyperpolarization current, during high frequency firing in rat subthalamic nucleus cells. J Physiol 2008; 586: 817-833. (Pubitemid 351194120)
83. Tepper JM, Lee C. GABAergic control of substantia nigra dopaminergic neurons. In: Progress in Brain Research. Amsterdam: Elsevier, 2007; 189-208.
84. A receptor-mediated inhibition of rat substantia nigra dopaminergic neurons by pars reticulata projection neurons. J Neurosci 1995; 15: 3092-3103.
85. Tillerson JL, Cohen AD, Caudle WM, et al. Forced nonuse in unilateral Parkinsonian rats exacerbates injury. J Neurosci 2002; 22: 6790-6799.
86. Tillerson JL, Cohen AD, Philhower J, et al. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J Neurosci 2001; 21: 4427-4435. (Pubitemid 32538569)
87. Tolosa E, Mart MJ, Valldeoriola F, et al. History of levodopa and dopamine agonists in Parkinson's disease treatment. Neurology 1998; 50: S2-S10. (Pubitemid 28270372)
88. Ungerstedt U. Post-synaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system. Acta Physiol Scand Suppl 1971; 367: 69-93.
89. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970; 24: 485-493.
90. Ungerstedt U, de Ajuriaquerra J. Mechanism of action of L-DOPA studied in an experimental Parkinson model. In: Monoamines and the Central Grey Nuclei: Proceedings of the Bel Air Symposium, 1971; 165-170.
91. Ungerstedt U, Ljunberg T. Central dopamine neurons and sensory processing. J Psychiatr Res 1974; 11: 149-150.
92. Ungerstedt U, Marshall JF, Jonsson G, et al. Nerve degeneration in functional studies: experiments illustrating the problem of lesion specificity and compensatory supersensitivity. In: Chemical Tools in Catecholamine Research. Amsterdam: North-Holland, 1975; 311-318.
93. Voom P, Gerfen CR, Groenewegen HJ. Compartmental organization of the ventral striatum of the rat: immunohistochemical distribution of enkephalin, substance P, dopamine and calcium binding protein. J Comp Neurol 1989; 289: 189-201.
94. Warnke PC. STN stimulation and neuroprotection in Parkinson's disease - when beautiful theories meet ugly facts. J Neurol Neurosurg Psychiatry 2005; 76: 1186-1187.
95. Weiner WJ. The initial treatment of Parkinson's disease should begin with levodopa. Mov Disord 1999; 14: 716-724. (Pubitemid 29509612)
96. Wilson CJ, Shephard G. Basal ganglia. In: The Synaptic Organization of the Brain. New York: OUP, 1990; 279-316.
97. Windels F, Bruet N, Poupard A, et al. Effects of high frequency stimulation of subthalamic nucleus on extracellular glutamate and GABA in substantia nigra and globus pallidus in the normal rat. Eur J Neurosci 2000; 12: 4141-4146. (Pubitemid 30836301)
98. Windels F, Carcenac C, Poupard A, et al. allidal Origin of GABA release within the substantia nigra pars reticulata during high-frequency stimulation of the subthalamic nucleus. J Neurosci 2005; 25: 5079-5086. (Pubitemid 40712852)
99. Wright AK, Arbuthnott GW. The influence of the subthalamic nucleus upon the damage to the dopamine system following lesions of globus pallidus in rats. Eur J Neurosci 2007; 26: 642-648.
100. Wright AK, Atherton JF, Norrie L, et al. Death of dopaminergic neurones in the rat substantia nigra can be induced by damage to globus pallidus. Eur J Neurosci 2004; 20: 1737-1744. (Pubitemid 39471566)
101. Wright AK, McLaughlin KE, Atherton JF, et al. Lesions of the rat globus pallidus, which increase subthalamic nucleus activity, cause dopamine cell death. In: Nicholson LFB, Faull RLM, eds. Vol 52. The Basal Ganglia VII. New York: Kluwer Academic/Plenum Publishers, 2002; 457-464.
102. Wright AK, Miller C, Williams M, et al. Microglial activation is not prevented by tacrolimus but dopamine neuron damage is reduced in a rat model of Parkinson's disease progression. Brain Res 2008; 1216: 78-86.
103. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease - a double-edged sword. Neuron 2002; 35: 419-432. (Pubitemid 34879943)